ProSight Overview
ProSight is a medical device startup spun out of the Weizmann Institute of Science, developing a real-time ex-vivo biopsy samples scanner, potentially transforming prostate cancer diagnosis based on new, never-used-before biomarkers, addressing the limitations in all biopsy procedures. Need: Current methods in prostate cancer biopsy often miss tumors and lead to unnecessary procedures, resulting in patient anxiety, delayed treatment, and increased healthcare costs. Science: Zinc depletion in the prostate is the most accurate cancer biomarker known to science. (~1,800 articles in the last 25 Yrs) Novelty: Fast X-ray fluorescence scanning of the fresh biopsy samples during biopsy, for computing the cancer severity Clinical Use and Impact: During-biopsy, real-time cancer grading of the biopsy samples, eliminating randomness, allowing real-time guidance to suspicious regions - thus harvesting the most relevant samples. ~ Doubling Detection Rate and Cancer Characterization Accuracy Minimizing over/under treatment; earlier detection (Zn depletion precedes other cancer signs) maximizing the likelihood of detecting all tumors in the 1st biopsy, Readiness: Prototype; Patents (one granted); Successful Clinical studies in local MCs; Regulatory Strategy (510k) in place for the 1st release, backed by Hogan Lovells; money injection to date - ca $6M (bootstrap mode); article published (https://www.mdpi.com/2075-4418/13/3/424/pdf) Plans: Raising round A - $8M (the Israeli Innovation Authority will add non-dilutive funding ~$4M); Completion of product development (first generation) and FDA submission - in 12 months following investment; FDA clearance and 1st product launch - 18 months; Reimbursement and start-of-sales - 24 months. Team: High-tech veterans with diverse executive roles, led a number of breakthrough projects. Capable of initiating all critical paths. Achievable goal: Become Standard of Care in prostate cancer biopsy and diagnosis - a $10Bn market.
Cumulative Funding Raised Over Time ($)
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6.05M |
| Last funding | $50K |
| Stage | Seed |
| Rounds | 2 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | prosight.site |
Locations
Ha-Nevi'im St 65, Bat Yam, Israel
Photos & Videos
No files yet
ProSight Business
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Simulation & ImagingBiologicalsArtificial IntelligenceTags (10)
software-developmentdigital-healthcarehospitalsdata-analyticsdiagnosticshealthcare-providersbig-datacancerpatent-pendingcancer-diagnosticsGeographic Markets
AmericasEuropeAsiaProSight Financials
Cumulative Funding Raised Over Time ($)
Private Equity Funding
Non-Equity Funding
ProSight Lifecycle
Cumulative Funding Raised Over Time
All Events
ProSight News
0 articlesNo news articles.
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
ProSight Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 95/100 |
| Missing | video or image, news, markets, external profiles |
| BI Verification | Yotam Maman |
| Registrar ID | 514844323 |
| Phone | 0544843220|0505172233 |
| Creator | Avi Simon |
| Creator email | avi@neodigma.net |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2020-10-12T00:00:00.000Z |
| Created | 2020-01-13T00:00:00.000Z |
| Claimed | Yes |